Glen Santangelo

Q: What is Glen Santangelo's success rate?

Glen Santangelo currently has a success rate of 80.99297082749587.

Q: What is the average return of Glen Santangelo's calls?

Their stock ratings have generated an average return of 12.247677426934699.

Barclays | Healthcare

Glen Santangelo is an analyst from Barclays specializing in the Healthcare sector. Ranked #1768 out of 4655 analysts, they have issued 62 stock ratings with a success rate of 80.99% and an average return of 12.25%.

Glen Santangelo has a well-established track record, with 62 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 80.99% and an average return of 12.25%, underscoring their expertise and ability to identify winning opportunities for investors.

#1768

Out of 4655

Total Ratings

+80.99%

Success Rate

+12.25%

Average Return

Recent Ratings Analysis

PHR

Hold

May 15, 2026

Target

$10.00

Current

$8.77

Performance

0.00%

Glen Santangelo rated PHR as Equal-Weight on May 15, 2026, setting a price target of 10. The Hold stance appears justified, as shares hovered around 8.77 with a 0.00% move.

DOCS

Hold

May 15, 2026

Target

$20.00

Current

$18.97

Performance

0.00%

On May 15, 2026, DOCS was given a Equal-Weight rating by Glen Santangelo, with a target price of 20. Market indecision, reflected in sideways trading near 18.97, supported the cautious call.

TEVA

Buy

May 06, 2026

Target

$40.00

Current

$34.29

Performance

-5.64%

TEVA received a Overweight rating from Glen Santangelo on May 06, 2026, aiming for 40. The rating hasn’t played out as hoped, with the stock trading 5.64% below expectations.

CTEV

Buy

Apr 24, 2026

Target

$28.00

Current

$13.87

Performance

—

On Apr 24, 2026, Glen Santangelo published a Overweight outlook on CTEV, with a target of 28. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 13.87.

AMPH

Hold

Apr 08, 2026

Target

$23.00

Current

$16.87

Performance

-17.30%

Glen Santangelo on Apr 08, 2026 assigned AMPH a Equal-Weight rating, with a price target of 23. The call successfully avoided chasing as shares lost 17.30%.

PHAT

Buy

Mar 27, 2026

Target

$18.00

Current

$11.87

Performance

12.19%

On Mar 27, 2026, Glen Santangelo reaffirmed PHAT with a Overweight rating, targeting 18. The recommendation was supported by strong follow-through as the stock rose from 11.87 to 11.87.

PCRX

Hold

Mar 26, 2026

Target

$25.00

Current

$22.64

Performance

—

PCRX was rated Equal-Weight by Glen Santangelo on Mar 26, 2026, with a price objective of 25. Flat performance suggests the Hold view was reasonable.

TDOC

Hold

Mar 26, 2026

Target

$7.00

Current

$6.36

Performance

—

On Mar 26, 2026, Glen Santangelo initiated coverage on TDOC with a Equal-Weight rating and target of 7. The stock’s lack of movement around 6.36 aligned with a cautious approach.

ALVO

Sell

Mar 24, 2026

Target

$4.00

Current

$3.31

Performance

5.75%

Glen Santangelo issued a Underweight recommendation for ALVO on Mar 24, 2026, price target set at 4. The bearish outlook played out, as shares fell from 3.31 to 3.31.

VTRS

Buy

Mar 24, 2026

Target

$17.00

Current

$16.48

Performance

23.35%

On Mar 24, 2026, VTRS was evaluated by Glen Santangelo, who gave a Overweight rating and target of 17. This case illustrates how a timely bullish rating can translate into tangible gains of 23.35%.

PGNY

Buy

Mar 20, 2026

Target

$23.00

Current

$23.25

Performance

28.24%

Glen Santangelo rated PGNY as Overweight on Mar 20, 2026, setting a price target of 23. The call has proven timely, with shares rising 28.24% toward the price target of 23.

ALGN

Buy

Mar 17, 2026

Target

$200.00

Current

$157.25

Performance

-10.71%

On Mar 17, 2026, ALGN was given a Overweight rating by Glen Santangelo, with a target price of 200. Despite the Buy call, shares fell from 157.25 to 157.25, challenging the optimistic stance.

HIMS

Buy

Mar 11, 2026

Target

$29.00

Current

$25.05

Performance

-3.21%

HIMS received a Overweight rating from Glen Santangelo on Mar 11, 2026, aiming for 29. Price action was muted, as shares hovered around 25.05 despite the bullish outlook.

TALK

Hold

Mar 10, 2026

Target

$5.50

Current

$5.20

Performance

0.19%

On Mar 10, 2026, Glen Santangelo published a Equal-Weight outlook on TALK, with a target of 5.5. Sideways action left the Hold view intact, with no major move since 5.2.

BHC

Hold

Feb 25, 2026

Target

$8.00

Current

$5.42

Performance

-11.29%

Glen Santangelo on Feb 25, 2026 assigned BHC a Equal-Weight rating, with a price target of 8. The call successfully avoided chasing as shares lost 11.29%.

CAH

Buy

Feb 24, 2026

Target

$258.00

Current

$195.20

Performance

-13.62%

On Feb 24, 2026, Glen Santangelo reaffirmed CAH with a Overweight rating, targeting 258. Shares slid 13.62% despite the recommendation, highlighting downside risks.

OGN

Sell

Feb 24, 2026

Target

$8.00

Current

$13.40

Performance

64.62%

OGN was rated Underweight by Glen Santangelo on Feb 24, 2026, with a price objective of 8. Bearish sentiment was justified as the stock retreated to 13.4.

MCK

Buy

Feb 18, 2026

Target

$1.05

Current

$760.57

Performance

-19.68%

On Feb 18, 2026, Glen Santangelo initiated coverage on MCK with a Overweight rating and target of 1.05. The Buy call has yet to be validated as shares remain -759.52 away from the target.

HQY

Buy

Feb 18, 2026

Target

$118.00

Current

$82.17

Performance

6.56%

Glen Santangelo issued a Overweight recommendation for HQY on Feb 18, 2026, price target set at 118. Investors following the Buy call captured upside momentum, with shares now at 82.17.

COR

Buy

Feb 13, 2026

Target

$425.00

Current

$257.71

Performance

-28.58%

On Feb 13, 2026, COR was evaluated by Glen Santangelo, who gave a Overweight rating and target of 425. Investors saw limited payoff as shares fell short of the 425 target.

NVST

Buy

Feb 11, 2026

Target

$34.00

Current

$23.22

Performance

-23.27%

Glen Santangelo rated NVST as Overweight on Feb 11, 2026, setting a price target of 34. The stock has underperformed, dropping 23.27% despite the bullish target of 34.

IDXX

Buy

Feb 05, 2026

Target

$800.00

Current

$528.79

Performance

-17.84%

On Feb 05, 2026, IDXX was given a Overweight rating by Glen Santangelo, with a target price of 800. Despite the Buy call, shares fell from 528.79 to 528.79, challenging the optimistic stance.

GDRX

Hold

Jan 22, 2026

Target

$2.75

Current

$2.43

Performance

-5.45%

GDRX received a Hold rating from Glen Santangelo on Jan 22, 2026, aiming for 2.75. The Hold stance proved prudent, with the market softening by 5.45%.

MDLN

Buy

Jan 12, 2026

Target

$50.00

Current

$36.19

Performance

-15.29%

On Jan 12, 2026, Glen Santangelo published a Overweight outlook on MDLN, with a target of 50. Market action contradicted the Buy thesis, as shares slipped to 36.19.

COLL

Buy

Jan 09, 2026

Target

$58.00

Current

$33.78

Performance

-25.82%

Glen Santangelo on Jan 09, 2026 assigned COLL a Overweight rating, with a price target of 58. The call has struggled to gain traction, with shares losing 25.82%.

ELAN

Buy

Dec 09, 2025

Target

$30.00

Current

$19.86

Performance

-2.79%

On Dec 09, 2025, Glen Santangelo reaffirmed ELAN with a Overweight rating, targeting 30. Market indecision has kept the 30 target in a holding pattern.

AS

Buy

Dec 09, 2025

Target

$49.00

Current

$32.84

Performance

-15.10%

AS was rated Overweight by Glen Santangelo on Dec 09, 2025, with a price objective of 49. This case shows how bullish projections can fail, with the stock now below 32.84.

ANIP

Buy

Dec 09, 2025

Target

$100.00

Current

$78.01

Performance

-4.48%

On Dec 09, 2025, Glen Santangelo initiated coverage on ANIP with a Overweight rating and target of 100. Neutral price movement of -4.48% leaves room for interpretation.

AMRX

Buy

Dec 09, 2025

Target

$15.00

Current

$11.93

Performance

-0.33%

Glen Santangelo issued a Overweight recommendation for AMRX on Dec 09, 2025, price target set at 15. The target of 15 remains in play, though confirmation will depend on future moves.

ZTS

Hold

Dec 09, 2025

Target

$136.00

Current

$74.22

Performance

-35.88%

On Dec 09, 2025, ZTS was evaluated by Glen Santangelo, who gave a Equal-Weight rating and target of 136. The Hold call avoided chasing into subsequent weakness of 35.88%.

XERS

Buy

Dec 09, 2025

Target

$9.00

Current

$6.24

Performance

-10.98%

Glen Santangelo rated XERS as Overweight on Dec 09, 2025, setting a price target of 9. The stock has underperformed, dropping 10.98% despite the bullish target of 9.

TARS

Buy

Dec 09, 2025

Target

$100.00

Current

$62.38

Performance

-21.58%

On Dec 09, 2025, TARS was given a Overweight rating by Glen Santangelo, with a target price of 100. Despite the Buy call, shares fell from 62.38 to 62.38, challenging the optimistic stance.

XRAY

Sell

Dec 09, 2025

Target

$12.00

Current

$10.07

Performance

-9.36%

XRAY received a Underweight rating from Glen Santangelo on Dec 09, 2025, aiming for 12. Investors who stayed short missed an upside surprise of -9.36%.

HSIC

Buy

Dec 09, 2025

Target

$86.00

Current

$72.72

Performance

-2.31%

On Dec 09, 2025, Glen Santangelo published a Overweight outlook on HSIC, with a target of 86. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 72.72.

WAY

Buy

Feb 11, 2025

Target

$51.00

Current

$17.93

Performance

-57.79%

Glen Santangelo on Feb 11, 2025 assigned WAY a Buy rating, with a price target of 51. The call has struggled to gain traction, with shares losing 57.79%.

Frequency Asked Questions

Who is Glen Santangelo?

Glen Santangelo is an analyst from Barclays specializing in the Healthcare sector.

What is Glen Santangelo's success rate?

Glen Santangelo currently has a success rate of +80.99%.

How many ratings has Glen Santangelo issued?

Glen Santangelo has issued 62 stock ratings so far.

What is the average return of Glen Santangelo's calls?

Their stock ratings have generated an average return of +12.25%.

What is Glen Santangelo's ranking?

Glen Santangelo is ranked #1768 out of 4655 analysts.

What types of ratings does Glen Santangelo give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Glen Santangelo?

You can follow Glen Santangelo by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Glen Santangelo?

Their latest rating was a Hold on PHR issued on 2026-05-15.